Outcomes of rescue exchange transfusion in severe neonatal hyperbilirubinemia
Öz
Purpose: Urgent treatment in newborns with severe hyperbilirubinemia is the removal of bilirubin from the body by exchange transfusion (ET) as the main treatment modality. The aim of this study was to evaluate the outcomes of newborns with severe hyperbilirubinemia who underwent ET in two neonatal ıntensive care units (NICUs).
Materials and Methods: The clinical data were collected of 28 newborns who had undergone rescue exchange transfusions after hospitalization with a diagnosis of severe hyperbilirubinemia in NICUs of a university hospital and a state hospital.
Results: Evaluation was made of 28 newbons with a median serum bilirubin level on admission of 31.2 (20.3-36.8) mg/dL. The leading cause for exchange transfusion was hemolytic jaundice (67.8%), followed by inadequate feeding (14%). The most common cause of hyperbilirubinemia was Rh incompatibility. The reported rate of adverse events associated with exchange transfusion was 71%. The most common complications due to ET were thrombocytopenia and anemia. Four infants died after the ET therapy. Acute bilirubin encephalopathy (ABE) was detected in 39% of the newborns. Serum bilirubin and bilirubin/albumin ratios were found to be high in newborns with ABE.
Conclusion: Newborns with severe hyperbilirubinemia, especially when related to hemolytic jaundice, may need rescue ET. As newborns with severe hyperbilirubinemia with a high bilirubin/albumin ratio are at risk of ABE, ET should be considered in these cases
Anahtar Kelimeler
Newborn, Newborn, exchange transfusion, hyperbilirubinemia, acute bilirubin encephalopathy
Destekleyen Kurum
no Funding
Teşekkür
Dear Editor
Please accept this paper and the attached main text, Rescue exchange transfusion in severe neonatal hyperbilirubinemia: a two-center experience", which we would like to submit for possible publication to Çukurova Medical Journal.
Urgent treatment in newborns with severe hyperbilirubinemia is removal of bilirubin from the body by exchange transfusion as a main treatment modality. We aimed to evaluate the outcomes of newborns with severe hyperbilirubinemia who underwent ET in two-NICUs.
We collected clinical data of 28 newborns undergone rescue exchange transfusion after hospitalization with diagnosis of severe hyperbilirubinemia in NICUs of a university hospital and a state hospital
Results: The median postnatal age at admission was 3 (1-6) days. The most common cause of hyperbilirubinemia was Rh incompatibility. After ET, serum bilirubin levels, albumin, AST and count of thrombocyte were decreased. The most common complications due to ET were thrombocytopenia and anemia. Acute ABE was detected in 39% of patients. Serum bilirubin and bilirubin / albumin ratios were found to be high in patients with ABE
Ethical approval was provided from the Human Research Ethics Committee of Cumhuriyet University before the study, and the study was carried out in accordance with the Helsinki Declaration. Verbal and written informed consents for the study to participation and publication were obtained from patients and their parents, on the condition that patients' anonymity must be preserved.
We confirm that this study is original, no conflict of interest related to this study and has not been published elsewhere nor is it currently under consideration for publication elsewhere.
We hope that you will afford us the opportunity to be accepted as an author. For any information concerning this manuscript, please contact me preferably by fatihkilicbay@cumhuriyet.edu.tr Thank you for your time and consideration of this manuscript. I look forward to hearing from you soon.
Yours sincerely,
Dr.Fatih Kılıçbay, MD, Division of Neonatology, Department of Pediatrics, Cumhuriyet University, Faculty of Medicine, Sivas, Turkey. Zip Code: 58140.
Phone: +90 0346 258 3033/ +90 fatihkilicbay@cumhuriyet.edu.tr , Fax: 03462580032.
E-mail: fatihkilicbay@cumhuriyet.edu.tr
Kaynakça
- Erdeve O, Okulu E, Olukman O, Ulubas D, Buyukkale G, Narter F et al. Turkish Neonatal Jaundice Registry Collabolators. The Turkish Neonatal Jaundice Online Registry: A national root cause analysis. PLoS One.2018;13:e0193108.
- Olusanya BO, Ogunlesi TA, Kumar P, Boo NY, Iskander IF, de Almeida MF et al. Management of late-preterm and term infants with hyperbilirubinaemia in resource-constrained settings. BMC Pediatr.2015;15:39.
- American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics.2004;114:297-16.
- Hameed NN, Na' Ma AM, Vilms R, Bhutani VK. Severe neonatal hyperbilirubinemia and adverse short-term consequences in Baghdad, Iraq. Neonatology. 2011;100:57-3.
- English M, Ngama M, Musumba C, Wamola B, Bwika J, Mohammed S et al. Causes and outcome of young infant admissions to a Kenyan district hospital. Arch Dis Child. 2003;88:438-43.
- Mwaniki MK, Atieno M, Lawn JE, Newton CR. Long-term neurodevelopmental outcomes after intrauterine and neonatal insults: a systematic review. Lancet. 2012;379:445-52.
- Çoban A, Türkmen MK, Gürsoy T. Turkish Neonatal Society guideline to the approach, follow-up, and treatment of neonatal jaundice. Turk Arch Pediatr. 2018;53:172-9.
- Wolf MF, Childers J, Gray KD, Chivily C, Glenn M, Jones L et al. Exchange transfusion safety and outcomes in neonatal hyperbilirubinemia. J Perinatol. 2020;40:1506-12.
- Nasseri F, Mamouri GA, Babaei H. Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn. Saudi Med J.2006;27:1827-30.
- Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the term newborn: a kinder, gentler approach. Pediatrics.1992;89:809-18.
